By a News Reporter-Staff News Editor at Cancer Gene Therapy Week -- Current study results on Biotechnology have been published. According to news reporting originating in Miyagi, Japan, by NewsRx journalists, research stated, "Increasing evidence supports the important role of cancer stem cells (CSCs). Many reports suggest that epithelial cell adhesion molecule (EpCAM) is a useful marker for cancer stem cells in hepatocellular carcinoma (HCC)."
The news reporters obtained a quote from the research from Tohoku University Hospital, "To elucidate the mechanisms of cancer stem cells, the development of specific molecular targeted drugs has become very important. In the present study, we examined the EpCAM expression pattern and its characteristic expression in resected HCC. We studied the drug resistance of EpCAM expression cells. EpCAM expression was detected significantly more frequently with hepatitis B virus (HBV) than with other etiologies. In HCC resection patients who had received prior treatment (transcatheter arterial embolization or hepatic arterial infusion chemotherapy), EpCAM was strongly expressed. In particular, very strong expression was observed after hepatic arterial infusion chemotherapy. The PLC/PRF/5 human HCC cell line expressed bimodal EpCAM, and EpCAM-positive cells had CSC cell potency. The EpCAM expression in EpCAM-positive cells increased significantly by treatment with cisplatin. EpCAM-positive cells showed better viability than EpCAM-negative cells when treated with ciplatin."
According to the news reporters, the research concluded: "Collectively, our results suggest that cancer stem cells are highly expressed in hepatitis B and have potential anticancer drug resistance."
For more information on this research see: Expression of EpCAM increases in the hepatitis B related and the treatment-resistant hepatocellular carcinoma. Biomed Research International, 2014;2014():172913 (see also Biotechnology).
Our news correspondents report that additional information may be obtained by contacting O. Kimura, Division of Gastroenterology, Tohoku University Hospital, 1-1 Seiryo-Machi, Aoba-ku, Sendai, Miyagi 980-8574, Japan. Additional authors for this research include Y. Kondo, T. Kogure, E. Kakazu, M. Ninomiya, T. Iwata, T. Morosawa and T. Shimosegawa.
Keywords for this news article include: Asia, Biotechnology, Japan, Drugs, Miyagi, Oncology, Hepatitis, Chemotherapy, Liver Diseases, Gastroenterology, Infectious Disease, Stem Cell Research, Cancer Gene Therapy, Hepatocellular Carcinoma, Digestive System Diseases.
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC